Symbols / SRNE
SRNE Chart
About
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, provides therapeutic solutions in the United States and internationally. It offers chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, and antibody-drug conjugates, as well as Seprehvec, SOFUSA, RTX, and SEMDEXA. The company also develops antiviral therapies and vaccines, including Abivertinib, COVI-MSC, COVI-AMG, COVIDROPS, and COVI SHIELD; and diagnostic test solutions, such as COVISTIX, COVITRACK, and Virex. Its products are used for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases treatment. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.38M |
| Enterprise Value | 135.48M | Income | -548.00M | Sales | 64.27M |
| Book/sh | -0.38 | Cash/sh | 0.15 | Dividend Yield | — |
| Payout | 0.00% | Employees | 949 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 0.02 | P/B | -0.01 | P/C | — |
| EV/EBITDA | -0.40 | EV/Sales | 2.11 | Quick Ratio | 0.34 |
| Current Ratio | 0.41 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.43 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | 31.10% | Earnings | 2023-05-15 15:00 | ROA | -40.81% |
| ROE | — | ROIC | — | Gross Margin | -245.01% |
| Oper. Margin | -5.11% | Profit Margin | 0.00% | Shs Outstand | 551.28M |
| Shs Float | 539.11M | Short Float | 11.96% | Short Ratio | 4.96 |
| Short Interest | — | 52W High | 0.10 | 52W Low | 0.00 |
| Beta | 1.46 | Avg Volume | 350.78K | Volume | 501.68K |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | -3.85% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-1.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
- Sorrento Therapeutics Stock: From Nasdaq Delisting To Penny-Stock Limbo - AD HOC NEWS Sun, 04 Jan 2026 08
- Scilex Holding announces 1-for-35 reverse stock split - Investing.com ue, 15 Apr 2025 07
- Sorrento (SRNE) Stock Has Over 700% Upside Potential, Says Analyst - Yahoo Finance Mon, 25 Nov 2019 08
- From Sorrento to SRNEQ: Anatomy of a Fallen Biotech High?Flyer - AD HOC NEWS Fri, 13 Feb 2026 13
- Sorrento (SRNE) Stock Is up 140% in Two Days. How Much Higher Can It Go? - Nasdaq Mon, 18 May 2020 07
- 5 Investors Betting Big on Sorrento Therapeutics (SRNE) Stock - InvestorPlace Mon, 13 Feb 2023 08
- Where Will Sorrento Therapeutics Be in 1 Year? - The Motley Fool Fri, 22 Jan 2021 08
- A SPAC, Spinoff, And Short Squeeze Walk Into A Bar (NASDAQ:SCLX) - Seeking Alpha ue, 24 Jan 2023 08
- Scilex Holding Company Announces that the U.S. Bankruptcy - GlobeNewswire Fri, 31 Jan 2025 08
- Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today? - InvestorPlace Mon, 13 Feb 2023 08
- Why Sorrento Therapeutics Stock Crashed Today - Nasdaq Wed, 22 Feb 2023 08
- Novavax and Sorrento Therapeutics: Are These Beaten-Down Coronavirus Stocks a Bargain? - The Motley Fool Mon, 16 Nov 2020 08
- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9% majority-owned subsidiary of Sorrento Therapeutics, Inc.) (Nasdaq: SRNE, “Sorrento”), and Vickers Vantage Corp. I Announce Effectiveness of Registration Statement on For - Yahoo Finance Mon, 31 Oct 2022 07
- 3 High-Risk, High-Reward Stocks to Add to Your Watch List - The Motley Fool ue, 22 Sep 2020 07
- BlackRock Increases Position in Sorrento Therapeutics (SRNE) - Nasdaq Fri, 03 Feb 2023 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TaxEffectOfUnusualItems | -754.41K | -4.02M |
| TaxRateForCalcs | 0.00 | 0.07 |
| NormalizedEBITDA | -364.52M | -384.43M |
| TotalUnusualItems | -175.41M | -55.41M |
| TotalUnusualItemsExcludingGoodwill | -175.41M | -55.41M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -572.84M | -428.32M |
| ReconciledDepreciation | 13.24M | 12.46M |
| ReconciledCostOfRevenue | 24.53M | 4.71M |
| EBITDA | -539.93M | -439.84M |
| EBIT | -553.17M | -452.30M |
| NetInterestIncome | -8.57M | -10.22M |
| InterestExpense | 8.57M | 10.22M |
| NormalizedIncome | -398.19M | -376.93M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -572.84M | -428.32M |
| TotalExpenses | 441.34M | 420.95M |
| TotalOperatingIncomeAsReported | -504.31M | -401.45M |
| DilutedAverageShares | 419.31M | 294.77M |
| BasicAverageShares | 419.31M | 294.77M |
| DilutedEPS | -1.37 | -1.45 |
| BasicEPS | -1.37 | -1.45 |
| DilutedNIAvailtoComStockholders | -572.84M | -428.32M |
| AverageDilutionEarnings | 0.00 | 0.00 |
| NetIncomeCommonStockholders | -572.84M | -428.32M |
| NetIncome | -572.84M | -428.32M |
| MinorityInterests | 4.91M | 813.00K |
| NetIncomeIncludingNoncontrollingInterests | -577.76M | -429.14M |
| NetIncomeContinuousOperations | -577.76M | -429.14M |
| EarningsFromEquityInterestNetOfTax | -18.43M | -126.00K |
| TaxProvision | -2.42M | -33.52M |
| PretaxIncome | -561.75M | -462.53M |
| OtherIncomeExpense | -174.67M | -84.26M |
| OtherNonOperatingIncomeExpenses | 736.00K | -28.84M |
| SpecialIncomeCharges | -98.81M | -40.10M |
| OtherSpecialCharges | 50.02M | 30.90M |
| ImpairmentOfCapitalAssets | 124.19M | 0.00 |
| RestructuringAndMergernAcquisition | -75.40M | 9.20M |
| GainOnSaleOfSecurity | -76.60M | -15.31M |
| NetNonOperatingInterestIncomeExpense | -8.57M | -10.22M |
| InterestExpenseNonOperating | 8.57M | 10.22M |
| OperatingIncome | -378.50M | -368.05M |
| OperatingExpense | 407.89M | 407.92M |
| DepreciationAmortizationDepletionIncomeStatement | 4.33M | 4.14M |
| DepreciationAndAmortizationInIncomeStatement | 4.33M | 4.14M |
| Amortization | 4.33M | 4.14M |
| AmortizationOfIntangiblesIncomeStatement | 4.33M | 4.14M |
| ResearchAndDevelopment | 221.23M | 206.92M |
| SellingGeneralAndAdministration | 182.34M | 196.86M |
| GrossProfit | 29.39M | 39.87M |
| CostOfRevenue | 33.45M | 13.03M |
| TotalRevenue | 62.84M | 52.90M |
| OperatingRevenue | 62.84M | 52.90M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| TreasurySharesNumber | 7.57M | 7.57M |
| OrdinarySharesNumber | 515.25M | 314.57M |
| ShareIssued | 522.82M | 322.14M |
| NetDebt | 11.78M | 105.94M |
| TotalDebt | 134.50M | 237.58M |
| TangibleBookValue | -235.78M | -260.48M |
| InvestedCapital | 16.81M | 221.35M |
| WorkingCapital | -231.55M | 33.54M |
| NetTangibleAssets | -235.78M | -260.48M |
| CapitalLeaseObligations | 99.09M | 94.97M |
| CommonStockEquity | -18.61M | 78.75M |
| TotalCapitalization | 525.00K | 189.38M |
| TotalEquityGrossMinorityInterest | -21.67M | 78.13M |
| MinorityInterest | -3.06M | -619.00K |
| StockholdersEquity | -18.61M | 78.75M |
| GainsLossesNotAffectingRetainedEarnings | 1.50M | 1.03M |
| TreasuryStock | 49.46M | 49.46M |
| RetainedEarnings | -1.96B | -1.39B |
| AdditionalPaidInCapital | 1.99B | 1.51B |
| CapitalStock | 52.00K | 32.00K |
| CommonStock | 52.00K | 32.00K |
| TotalLiabilitiesNetMinorityInterest | 494.51M | 616.69M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 166.59M | 477.24M |
| OtherNonCurrentLiabilities | 54.26M | 126.11M |
| DerivativeProductLiabilities | 300.00K | 35.70M |
| NonCurrentDeferredLiabilities | 7.69M | 121.37M |
| NonCurrentDeferredRevenue | 7.10M | 118.94M |
| NonCurrentDeferredTaxesLiabilities | 591.00K | 2.43M |
| LongTermDebtAndCapitalLeaseObligation | 104.34M | 194.06M |
| LongTermCapitalLeaseObligation | 85.21M | 83.43M |
| LongTermDebt | 19.13M | 110.63M |
| CurrentLiabilities | 327.92M | 139.45M |
| OtherCurrentLiabilities | 8.20M | 7.93M |
| CurrentDeferredLiabilities | 652.00K | 1.11M |
| CurrentDeferredRevenue | 652.00K | 1.11M |
| CurrentDebtAndCapitalLeaseObligation | 30.17M | 43.52M |
| CurrentCapitalLeaseObligation | 13.88M | 11.54M |
| CurrentDebt | 16.29M | 31.98M |
| OtherCurrentBorrowings | 16.29M | 31.98M |
| PayablesAndAccruedExpenses | 288.91M | 86.89M |
| CurrentAccruedExpenses | 241.39M | 59.48M |
| Payables | 47.52M | 27.41M |
| AccountsPayable | 47.52M | 27.41M |
| TotalAssets | 472.84M | 694.82M |
| TotalNonCurrentAssets | 376.47M | 521.83M |
| OtherNonCurrentAssets | 3.69M | 4.83M |
| InvestmentsAndAdvances | 17.18M | 51.27M |
| LongTermEquityInvestment | 17.18M | 51.27M |
| GoodwillAndOtherIntangibleAssets | 217.17M | 339.23M |
| OtherIntangibleAssets | 136.90M | 259.70M |
| Goodwill | 80.27M | 79.53M |
| NetPPE | 138.44M | 126.50M |
| AccumulatedDepreciation | -51.42M | -43.49M |
| GrossPPE | 189.85M | 169.99M |
| Leases | 16.16M | 15.53M |
| ConstructionInProgress | 18.23M | 7.88M |
| OtherProperties | 86.46M | 85.17M |
| MachineryFurnitureEquipment | 69.00M | 61.41M |
| Properties | 0.00 | 0.00 |
| CurrentAssets | 96.37M | 172.99M |
| OtherCurrentAssets | 3.14M | 7.48M |
| PrepaidAssets | 8.81M | 11.80M |
| Inventory | 9.98M | 8.11M |
| OtherInventories | -24.00K | 106.00K |
| FinishedGoods | 3.40M | 4.70M |
| RawMaterials | 6.60M | 3.30M |
| Receivables | 24.47M | 18.71M |
| AccountsReceivable | 24.47M | 18.71M |
| CashCashEquivalentsAndShortTermInvestments | 49.98M | 126.88M |
| OtherShortTermInvestments | 26.34M | 90.22M |
| CashAndCashEquivalents | 23.63M | 36.66M |
| Line Item | 2022-12-31 | 2021-12-31 |
|---|---|---|
| FreeCashFlow | -307.51M | -290.69M |
| RepurchaseOfCapitalStock | 0.00 | 0.00 |
| RepaymentOfDebt | -188.31M | -85.66M |
| IssuanceOfDebt | 96.07M | 49.74M |
| IssuanceOfCapitalStock | 402.33M | 201.82M |
| CapitalExpenditure | -13.66M | -8.87M |
| InterestPaidSupplementalData | 1.17M | 1.06M |
| IncomeTaxPaidSupplementalData | 29.00K | 1.20M |
| EndCashPosition | 23.63M | 36.66M |
| BeginningCashPosition | 36.66M | 56.46M |
| EffectOfExchangeRateChanges | -2.37M | 843.00K |
| ChangesInCash | -10.66M | -20.64M |
| FinancingCashFlow | 311.72M | 181.33M |
| CashFlowFromContinuingFinancingActivities | 311.72M | 181.33M |
| NetOtherFinancingCharges | 426.00K | |
| ProceedsFromStockOptionExercised | 1.20M | 15.42M |
| NetCommonStockIssuance | 402.33M | 201.82M |
| CommonStockPayments | 0.00 | 0.00 |
| CommonStockIssuance | 402.33M | 201.82M |
| NetIssuancePaymentsOfDebt | -92.24M | -35.91M |
| NetShortTermDebtIssuance | 96.07M | 49.74M |
| ShortTermDebtIssuance | 96.07M | 49.74M |
| NetLongTermDebtIssuance | -188.31M | -85.66M |
| LongTermDebtPayments | -188.31M | -85.66M |
| LongTermDebtIssuance | 0.00 | |
| InvestingCashFlow | -28.52M | 79.85M |
| CashFlowFromContinuingInvestingActivities | -28.52M | 79.85M |
| NetInvestmentPurchaseAndSale | 0.00 | 124.77M |
| SaleOfInvestment | 0.00 | 124.77M |
| NetBusinessPurchaseAndSale | -14.86M | -36.05M |
| PurchaseOfBusiness | -14.86M | -36.05M |
| NetPPEPurchaseAndSale | -13.66M | -8.87M |
| PurchaseOfPPE | -13.66M | -8.87M |
| OperatingCashFlow | -293.86M | -281.82M |
| CashFlowFromContinuingOperatingActivities | -293.86M | -281.82M |
| ChangeInWorkingCapital | 69.55M | -2.79M |
| ChangeInOtherWorkingCapital | -113.22M | -4.57M |
| ChangeInPayablesAndAccruedExpense | 191.16M | 16.76M |
| ChangeInAccruedExpense | 181.29M | 20.64M |
| ChangeInPayable | 9.87M | -3.88M |
| ChangeInAccountPayable | 9.87M | -3.88M |
| ChangeInPrepaidAssets | 6.80M | -5.74M |
| ChangeInInventory | -9.51M | -6.28M |
| ChangeInReceivables | -5.68M | -2.96M |
| ChangesInAccountReceivables | -5.68M | -2.96M |
| OtherNonCashItems | -64.12M | 61.25M |
| StockBasedCompensation | 74.85M | 90.19M |
| AssetImpairmentCharge | 124.19M | 0.00 |
| DeferredTax | -1.84M | -35.93M |
| DeferredIncomeTax | -1.84M | -35.93M |
| DepreciationAmortizationDepletion | 13.24M | 12.46M |
| DepreciationAndAmortization | 13.24M | 12.46M |
| Depreciation | 12.46M | |
| OperatingGainsLosses | 68.02M | 22.13M |
| EarningsLossesFromEquityInvestments | 18.43M | 126.00K |
| GainLossOnInvestmentSecurities | 76.60M | 15.31M |
| NetIncomeFromContinuingOperations | -577.76M | -429.14M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SRNE
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|